Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy

NCT ID: NCT03594188

Last Updated: 2020-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-23
• Study Completion Date: 2019-12-31

Brief Summary

Numerous studies found that anesthetic methods can influence the recurrence of tumor and the overall survival of patients after primary cancer surgery. Radiofrequency (RF) ablation is now widely used in clinic for treatment of hepatocellular carcinoma (HCC). Currently, diverse anesthetic methods, including general anesthesia (GA), epidural anesthesia and local anesthesia (LA), are used for RF ablation surgery. Using serum from HCC surgery patients randomized to receive either GA or LA during surgery, we investigated the effects of anesthetic methods on proliferation, migration and metastasis in HepG2 hepatic cancer cells in vitro.

Conditions

Hepatocellular Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

general anesthesia

Patients in this group will have RF ablation for treatment of HCC under general anesthesia.

Group Type: EXPERIMENTAL

anesthetic methods

Intervention Type: PROCEDURE

Patients will receive standard GA or LA for RF surgery.

local anesthesia

Patients in this group will have RF ablation for treatment of HCC under local anesthesia.

Group Type: ACTIVE_COMPARATOR

anesthetic methods

Intervention Type: PROCEDURE

Patients will receive standard GA or LA for RF surgery.

Interventions

anesthetic methods

Patients will receive standard GA or LA for RF surgery.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• patients with a single primary liver tumor of 3cm or smaller, who are scheduled for RF ablation surgery

Exclusion Criteria

• less than 18 or more than 65 years old;
• ASA Physical Status 4 or greater;
• previous surgery in liver (including radiofrequency ablation);
• severe systemic disease (heart, lung, kidney, or immune system);
• INR>1.5 or platelet count <45,000 cells/mm3;
• a history of addiction to opioids;
• with known extension beyond the liver;
• Child-Pugh Class C.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RenJi Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jie Tian

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Renji Hospital affliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Countries

China

Other Identifiers

HEP201807

Identifier Type: -

Identifier Source: org_study_id